A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Inclusion Criteria Concurrent Medication: Allowed: Localized therapy such as intralesional injections for Kaposi's sarcoma. Patients must have: HIV infection documented by a licensed HIV antibody ELISA confirmed by: Western blot, or positive HIV blood culture, or positive HIV serum antigen and second antibody test positive by a method other than ELISA. CD4+ counts >= 150 and <= 400 cells/mm3 within 2 weeks of study entry. 1. Anticipated need for cytotoxic chemotherapeutic agents within 4 weeks prior to entry. Alprazolam, carbamazepine, codeine, clarithromycin, dapsone, diazepam, diltiazem, erythromycin, estrogens, glucocorticoids, imipramine, itraconazole, ketoconazole, lidocaine, lovastatin, nifedipine, phenobarbital, phenytoin, quinidine, rifabutin, rifampin and warfarin. The following medications should be used with caution in most instances or not at all: terfenadine, astemizole, cisapride, triazolam and midazolam. Anticipated need for treatment with radiation therapy within 4 weeks prior to entry. 1. Treatment with cytotoxic chemotherapeutic agents within 4 weeks prior to entry. Patients who have previously received a protease inhibitor. Antiretroviral therapy within 2 weeks prior to enrollment. NOTE: Patients with a known intolerance to either retrovir or epivir are not eligible for Phase B of this study. NOTE: Patients with previous epivir (3TC) experience will not be eligible for Regimen 6 of this study (combination therapy with 141W94 and 1592U89). Treatment with immunomodulating agents, including but not limited to systemic corticosteroids, IL-2, alpha-IFN, beta-IFN, or gamma-IFN within 4 weeks prior to entry. Treatment with HIV immunotherapeutic vaccine within 3 months prior to entry. Treatment with radiation therapy within 4 weeks prior to entry. Patients with current alcohol or illicit drug use which, in the opinion of the principal investigator, may interfere with the patients' ability to comply with the dosing schedule and protocol evaluations.